Kallyope Stock

kallyope.comHealthcareFounded: 2015Funding to Date: $479.46MM

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis by integrating cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics that improve human health.

Register for Details

For more details on financing and valuation for Kallyope, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Kallyope.

Register Today

Team

Management Team

Juha Lauren Ph.D
Chief Business Officer
Maximilian Lombardo
Senior Data Research Associate
Tom Maniatis Ph.D
Co-Founder & Board Member
Charles Zuker Ph.D
Co-Founder
Ann Weber Ph.D
Senior Vice President - Drug Discovery
Brett Lauring
Chief Medical Officer
Nancy Thornberry
Chief Executive Officer & Board Member
Richard Axel MD
Co-Founder
Robert Anstey
Vice President, Business Development

Board Members

Joshua Wolfe
Lux Capital Management
Tony Evnin Ph.D
Amy Schulman JD
Polaris Partners
Timothy Kutzkey Ph.D
The Column Group
William Rieflin JD
Nancy Thornberry
Terry McGuire
Tom Maniatis Ph.D

Other companies like Kallyope in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM

News

Kallyope, a biotech company focused on identifying therapeutic opportunities involving the gut-brain axis, raised $21m in Series B financing